Some of the intriguing findings from the research in this issue include:
A nontoxic agent that moderates treatment side effects without unduly protecting malignant tumors has much to offer oncology, including: 1) a lower need for dose reduction or treatment delay; 2) an improvement in quality of life for the cancer patient; 3) less oncology staff time spent dealing with side effects and patient complaints; 4) a lower need for pharmaceuticals; 5) fewer adverse reactions. (Keith I. Block)
Visit http://ict.sagepub.com/content/vol3/issue4/ for free online access to this issue of Integrative Cancer Therapies, published by SAGE Publications.
About the Journal
Integrative Cancer Therapies focuses on evidence based and scientifically sound alternative, complementary, experimental, and traditional non-Western medical practices and their responsible integration into conventional health care. Edited by Dr. Keith Block, Medical and Scientific Director of the Institute for Integrative Cancer Care, Integrative Cancer Therapies spearheads a new and growing movement in cancer treatment--integrative care--patient-focused care that aims to improve health outcomes and quality of life.
About SAGE Publications
SAGE Publications is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students. SAGE Publications, a privately owned corporation, has principal offices in Thousand Oaks, California, and in London, United Kingdom. SAGE journals are available online via SAGE Journals Online at http://online.sagepub.com .
Integrative Cancer Therapies